Abstract Bevacizumab (Avastin™, Genentech) is a humanized monoclonal antibody
targeting vascular endothelial growth factor (VEGF), a critical angiogenic factor involved in …

The importance of vascular endothelial growth factor (VEGF) as a regulator of normal and
tumor blood vessel growth has been increasingly characterized over the past two decades …

Angiogenesis is essential for tumor growth, invasion and metastasis, and is mediated, at
least in part, by a large family of VEGF ligands and receptors. Ramucirumab, which is being …

Inhibiting the angiogenic process is a clever method of cancer care. Over the last decade,
some antiangiogenic compounds have been developed and approved for cancer treatment …

Angiogenesis is crucial to tumour initiation, survival and metastasis. Vascular endothelial
growth factor (VEGF) is one of the most important pro-angiogenic factors in cancer …

Antiangiogenesis agents that target the VEGF/VEGF receptor pathway have become an
important part of standard therapy in multiple cancer indications. With expanded clinical …

Simple Summary Several anti-angiogenic drugs have been approved for cancer treatment,
alone or in combination with other anti-tumoral agents. Angiogenesis inhibitors cause drug …

The critical role of angiogenesis in tumour growth and metastasis is now well established in
the literature. Growing tumours stimulate neovascularisation through the secretion of pro …

Angiogenesis, the formation of blood vessels, is essential for preparing a closed circulatory
system in the body, and for supplying oxygen and nutrition to tissues. Major diseases such …

The recent launch onto the market of five VEGFR inhibitors indicates the therapeutic value of
these agents and the importance of the research in the field of angiogenesis inhibitors for …